Association of plasma fibrinogen and development of complications in type 2 diabetes mellitus

Authors

  • Het V. Patel Department of Medicine, Dhiraj Hospital, SBKS MI and RC, Sumandeep Vidyapeeth, Pipariya, Vadodara, Gujarat, India
  • Rajesh S. Sumple Department of Medicine, Dhiraj Hospital, SBKS MI and RC, Sumandeep Vidyapeeth, Pipariya, Vadodara, Gujarat, India
  • Pooja Harshitha K. Department of Medicine, Dhiraj Hospital, SBKS MI and RC, Sumandeep Vidyapeeth, Pipariya, Vadodara, Gujarat, India
  • Kshitij R. Sumple Department of Medicine, Dhiraj Hospital, SBKS MI and RC, Sumandeep Vidyapeeth, Pipariya, Vadodara, Gujarat, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20231315

Keywords:

Fibrinogen, Diabetes mellitus, Complications

Abstract

Background: Fibrinogen is a glycoprotein produced by the liver that plays a crucial role in blood clotting. Elevated levels of fibrinogen have been associated with an increased risk of cardio vascular disease, stroke and other chronic conditions. Several studies have investigated the relationship between fibrinogen and diabetes mellitus. Furthermore, fibrinogen has been suggested to play a role in pathogenesis of diabetes and its complications by promoting inflammation and endothelial dysfunction. The aim of the study was done to study association of fibrinogen levels and development of complications of diabetes mellitus.

Methods: A cross sectional observational study was conducted at medicine department of Dhiraj Hospital, Vadodara. Total of 114 diabetes mellitus patients were studied. The level of fibrinogen as well as presence of various risk factors like smoking, hypertension, obesity, dyslipidemia and different microvascular and macro-vascular complications were assessed. There were no conflict of interest.

Results: Of 114 patients smoking, overweight, hypertension, uncontrolled diabetes and dyslipidemia was reported in 54.4%, 30.7%, 41.2%, 28.1% and 60.5% respectively. Microvascular complication like retinopathy, nephropathy and neuropathy was reported in 34.2%, 40.4% and 21.1% patients respectively. Macrovascular complications like coronary artery disease and stroke was reported in 20.2% and 16.7% patients respectively. Average level of fibrinogen was found higher amongst diabetic patients with microvascular as well as macrovascular complications.

Conclusions: Serum fibrinogen level was found to be higher among patients with poor glycemic control, dyslipidemia, hypertension and higher BMI. A positive correlation was found between the level of fibrinogen and various complications of diabetes mellitus.  

References

Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003;17(1):24-38.

Kreutz RP, Nystrom P, Kreutz Y, Miao J, Kovacs R, Desta Z, et al. Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin. Platelets. 2013;24(2):145-50.

Ajjan R, Grant PJ. Coagulation and atherothrombotic disease. Atherosclerosis. 2006;186(2):240-59.

Jain A, Gupta HL, Narayan S. Hyperfibrinogenemia in patients of diabetes mellitus in relation to glycemic control and urinary albumin excretion rate. J Assoc Physicians India. 2001;49:227-30.

Arbez M. The molecular basis of inherited afibrinogenaemia. Thromb Haemost. 2001;86(1):154-63.

Hanss M, Biot F. A database for human fibrinogen variants. Ann N Y Acad Sci. 2001;936:89-90.

Carrell N, McDonagh J. Functional defects in abnormal fibrinogens. Structural variants and interactions. 2019: 155-64.

Reeve EB, Franks JJ. Fibrinogen synthesis, distribution and degradation. Semin Thromb Hemost. 1974;1(2):129-83.

Fuller GM, Otto JM, Woloski BM, McGary CT, Adams MA. The effects of hepatocyte stimulating factor on fibrinogen biosynthesis in hepatocyte monolayers. J Cell Biol. 1985;101(4):1481-6.

Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet JL, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med. 2013;39(9):1535-46.

Flick MJ, Du X, Witte DP, Jirousková M, Soloviev DA, Busuttil SJ, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest. 2004;113(11):1596-606.

Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study. Diabetes Care. 1998;21(4):649-54.

Boulogne A, Vantyghem MC. Données épidémiologiques et critères de dépistage du syndrome métabolique [Epidemiological data and screening criteria of the metabolic syndrome]. Presse Med. 2004;33(10):662-5.

Yudkin JS, Juhan-Vague I, Hawe E, Humphries SE, Minno G, Margaglione M, et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism. 2004;53(7):852-7.

Zanetti M, Barazzoni R, Garibotto G, Davanzo G, Gabelli C, Kiwanuka E, et al. Plasma protein synthesis in patients with low-grade nephrotic proteinuria. Am J Physiol Endocrinol Metab. 2001;280(4):E591-7.

Schrem H, Klempnauer J, Borlak J. Liver-enriched transcription factors in liver function and development. Part I: the hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol Rev. 2002;54(1):129-58.

Elwood PC, Yarnell JW, Pickering J, Fehily AM, O'Brien JR. Exercise, fibrinogen, and other risk factors for ischaemic heart disease. Caerphilly Prospective Heart Disease Study. Br Heart J. 1993;69(2):183-7.

Mennen LI, Balkau B, Vol S, Cacès E, Eschwège E. Fibrinogen: a possible link between alcohol consumption and cardiovascular disease? DESIR Study Group. Arterioscler Thromb Vasc Biol. 1999;19(4):887-92.

Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 1991;91(3):191-205.

Eriksson AK, Ekbom A, Granath F, Hilding A, Efendic S, Ostenson CG. Psychological distress and risk of pre-diabetes and Type 2 diabetes in a prospective study of Swedish middle-aged men and women. Diabet Med. 2008;25(7):834-42.

Mohan A, Srinivasan V, Deepa R, Mohan V. Lipoprotein (a): role in diabetes and its vascular complications. J Assoc Physicians India. 2001;49:1100-5.

Kamath S, Lip GY. Fibrinogen: biochemistry, epidemiology and determinants. QJM. 2003;96(10):711-29.

Bembde AS. A study of plasma fibrinogen level in type-2 diabetes mellitus and its relation to glycemic control. Indian J Hematol Blood Transfus. 2012;28(2):105-8.

Ganda OP, Arkin CF. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care. 1992;15(10):1245-50.

Hong LF, Li XL, Luo SH, Guo YL, Zhu CG, Qing P, et al. Association of fibrinogen with severity of stable coronary artery disease in patients with type 2 diabetic mellitus. Dis Markers. 2014;2014:485687.

Costa LA, Canani LH, Lisbôa HR, Tres GS, Gross JL. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. Diabet Med. 2004;21(3):252-5.

Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia. 2001;44(9):1148-54.

Zhang J, Wang Y, Zhang R, Li H, Han Q, Wu Y, et al. Serum fibrinogen predicts diabetic ESRD in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;141:1-9.

Downloads

Published

2023-04-29

How to Cite

Patel, H. V., Sumple, R. S., Harshitha K., P., & R. Sumple , K. (2023). Association of plasma fibrinogen and development of complications in type 2 diabetes mellitus. International Journal of Research in Medical Sciences, 11(5), 1558–1562. https://doi.org/10.18203/2320-6012.ijrms20231315

Issue

Section

Original Research Articles